Giorgio V. Scagliotti, MD, PhD, on Doubling the Lung Cancer Cure Rate by 2025: A Realistic Goal
IASLC 2020 World Conference on Lung Cancer in Singapore
Giorgio V. Scagliotti, MD, PhD, of the University of Torino, talks about why he believes that many more patients with lung cancer can be cured within the next 4 years, given decreases in mortality rates, widespread use of targeted treatments and immunotherapies, and earlier diagnoses as a result of systematic screening with low-dose CT (Abstract PL05.08).
The ASCO Post Staff
Bruce E. Johnson, MD, of Dana-Farber Cancer Institute, offers his expert perspective on single-arm drug approvals for targeted agents between 2016 and 2020, the need for biom...
The ASCO Post Staff
Silvia Novello, MD, PhD, of the University of Turin, disc...
The ASCO Post Staff
Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, discusses Lung-MAP studies in which a higher tumor mutation burden determined by next-generation sequencing was linked...
The ASCO Post Staff
Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, invites his colleagues to enroll their patients in a large prospective study, for which he serves as Principal Investi...
The ASCO Post Staff
Roy S. Herbst, MD, PhD, of Yale University, discusses two key abstracts from the ADAURA trial: the use of osimertinib as adjuvant therapy for resected EGFR-mutated n...
Advertisement
Advertisement
